Alector vs Regenxbio
ALEC and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALEC and RGNX compare
Regenxbio is the larger company, worth 1.8 times as much as Alector ($504M against $284M).
Alector grew revenue faster over the last twelve months (151% versus 12.0% for Regenxbio).
Alector keeps more of each dollar of sales as profit, with a net margin of 23.9% compared with −113% at Regenxbio.
Alector scores higher on the StockData Score (12 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALEC | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | $284M | $504M |
| Share price | $2.54 | $7.64 |
| Change, 1 year | 89.6% | −34.1% |
| Change, 5 years | −88.1% | −77.2% |
| Beta (5Y) | 1.50 | 1.78 |
| Employees | 103 | 371 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.3× | – |
| P/S | 1.6× (better) | 2.9× |
| P/B | 2.4× (better) | 7.0× |
| EV/EBITDA | 3.7× | – |
| FCF yield | −52.9% | −49.5% (better) |
| Fair value | $8.10 | – |
| Margin of safety | 68.6% | – |
| Growth | ||
| Revenue growth (TTM) | 151% (better) | 12.0% |
| Revenue growth, 5Y average | −0.05% | 2.0% (better) |
| Profitability | ||
| Operating margin | 20.2% (better) | −94.1% |
| Net margin | 23.9% (better) | −113% |
| FCF margin | −86.5% (better) | −143% |
| Return on equity | 47.5% (better) | −138% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | −3.53 | – |
| Interest coverage | – | −3.9× |
| Current ratio | 4.10 (better) | 2.86 |
| Altman Z-score | −1.55 (better) | −3.83 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 85.8% | 64.2% |
| Held by insiders | 9.6% | 7.6% |
| Insider net buying, 12 months | −$1.0M | $9.6K (better) |
| Short interest, % of float | 8.3% | 16.7% |
Go deeper
- ALEC stock overview
- ALEC income statement
- ALEC valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.